NEW YORK and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: H

NEW YORK and TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP)

Helus Pharma, formerly known as Cybin NASDAQ: HELP, outlined its late-stage development plans for HL

Cybin (NASDAQ: HELP), doing business as Helus Pharma, held its Annual General and Special Meeting of

Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) ("Helus" or the "Company"), a clinical-st

TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or

Cybin NASDAQ: HELP, doing business as Helus Pharma, held its Annual General and Special Meeting of S

CEO Michael Halstead to participate in a fireside chat on September 23, 2026 at 9:00 a.m. EDT CEO Mi

Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a cli

Poster presentations further characterize clinical profile of HLP003 and  Phase 3 PARADIGM program e

Helus Pharma Chief Executive Officer Michael Halstead said the company expects a pivotal Phase III r

Cybin NASDAQ: HELP executives outlined plans for its late-stage depression program, including an exp

Helus Pharma Chief Executive Officer Michael Halstead said the company expects a pivotal Phase III r

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Alaunos rose 21.8% after adopting amended bylaws; Cheetah Net led gainers, while Xenon dropped 27.6%

Cybin Inc. (NASDAQ: HELP - Get Free Report) insider Eric So acquired 100,000 shares of the stock in

Inspire Medical, Cybin and Aveanna show overbought RSI readings above 70, signaling potential moment

CEO Michael Halstead to participate in a fireside chat on Wednesday, September 16, 2026 at 8:30 a.m.

CEO Michael Halstead to participate in a fireside chat on Monday, September 14, 2026 at 9:00 a.m. ED

CEO Michael Halstead to participate in a fireside chat on Friday, September 11, 2026 at 8:00 a.m. ED

Helus Pharma has built a proprietary psychedelic pipeline that currently spans MDD and GAD. The comp

TD Cowen analyst Ritu Baral maintains Helus Pharma (NASDAQ:HELP) with a Buy and raises the price

Former Intra-Cellular Therapies, Inc. (“Intra-Cellular”) executives bring complementary experience i

Helus Pharma (NASDAQ:HELP) reported quarterly losses of $(0.91) per share which beat the analyst con

- Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Offic

Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% a

Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clin

Former President of Intra-Cellular Therapies, Inc. was instrumental in building and scaling the comp

Wells Fargo analyst Benjamin Burnett initiates coverage on Helus Pharma (NASDAQ:HELP) with a Over

US stocks trade higher as Dow Jones gains over 350 points. Tech shares rise by 2% while consumer sta

US stocks rise, Nasdaq gains 1%. Hasbro Inc (HAS) up 8.6% on strong Q2 results and raised sales guid

Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM ProgramParticipant

Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program Participan

U.S. stocks mixed, Nasdaq falls 150 points. Abbott Labs beats Q2 estimates and raises guidance, sto

JB Hunt Transport Services Inc (JBHT) beat earnings and revenue estimates, causing shares to surge 7

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Helus Pharma (NASDAQ:HELP) with a B

Canaccord Genuity analyst Sumant Kulkarni maintains Helus Pharma (NASDAQ:HELP) with a Buy and low

Helus Pharma (NASDAQ:HELP) reported quarterly losses of $(0.85) per share which beat the analyst con

Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday'

- APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorde

Health officials explored restricting specific antidepressants among SSRI drugs-sources

Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to h

TD Cowen analyst Ritu Baral initiates coverage on Helus Pharma (NASDAQ:HELP) with a Buy rating an

Helus Pharma (Cybin) shares fall after Phase 2 anxiety drug results show symptom improvement, but pr

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Helus Pharma (NASDAQ:HELP) with a B

Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a cli

Helus Pharma (NASDAQ:HELP) reported quarterly losses of $(1.00) per share which missed the analyst c

Helus PharmaTM ("Helus") (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical com